Insider Selling: Intra-Cellular Therapies Inc. (ITCI) Chairman Sells 6,604 Shares of Stock

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Chairman Sharon Mates sold 6,604 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $17.48, for a total transaction of $115,437.92. Following the completion of the sale, the chairman now directly owns 1,088,707 shares of the company’s stock, valued at approximately $19,030,598.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Sharon Mates also recently made the following trade(s):

  • On Friday, January 5th, Sharon Mates sold 11,257 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $17.08, for a total transaction of $192,269.56.
  • On Monday, October 30th, Sharon Mates sold 18,750 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $15.75, for a total transaction of $295,312.50.

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) opened at $18.40 on Friday. The firm has a market cap of $1,000.00, a price-to-earnings ratio of -8.40 and a beta of 0.72. Intra-Cellular Therapies Inc. has a one year low of $7.85 and a one year high of $22.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.06 million. Intra-Cellular Therapies had a negative net margin of 28,038.35% and a negative return on equity of 27.40%. The company’s revenue was up 675.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.70) EPS. analysts expect that Intra-Cellular Therapies Inc. will post -2.13 earnings per share for the current year.

A number of equities research analysts have commented on ITCI shares. ValuEngine downgraded shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 5th. BidaskClub downgraded shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 12th. Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Canaccord Genuity started coverage on shares of Intra-Cellular Therapies in a research report on Friday, December 15th. They issued a “buy” rating and a $31.00 target price for the company. Finally, SunTrust Banks raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. Intra-Cellular Therapies has an average rating of “Buy” and a consensus target price of $25.56.

Several institutional investors have recently modified their holdings of ITCI. Perceptive Advisors LLC purchased a new position in shares of Intra-Cellular Therapies during the 3rd quarter worth $14,667,000. Wasatch Advisors Inc. boosted its stake in shares of Intra-Cellular Therapies by 65.1% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock worth $20,611,000 after acquiring an additional 654,400 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Intra-Cellular Therapies during the 3rd quarter worth $8,663,000. Dimensional Fund Advisors LP boosted its stake in shares of Intra-Cellular Therapies by 419.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 647,187 shares of the biopharmaceutical company’s stock worth $8,038,000 after acquiring an additional 522,565 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Intra-Cellular Therapies by 336.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock worth $7,213,000 after acquiring an additional 447,586 shares during the last quarter. Institutional investors and hedge funds own 74.47% of the company’s stock.

WARNING: This story was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.themarketsdaily.com/2018/01/12/insider-selling-intra-cellular-therapies-inc-itci-chairman-sells-6604-shares-of-stock.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply